Haverford Financial Services Inc. Purchases New Holdings in Stryker Corporation $SYK

Key Points

• Haverford Financial Services purchased 10,563 Stryker shares during the second quarter, valued at approximately $3.33 million. Institutional investors collectively own 77.09% of the company.
• Stryker reported quarterly earnings of $3.69 per share and revenue of $6.59 billion, exceeding analyst expectations, while revenue rose 9.4% year over year. The company maintained fiscal 2026 guidance of $14.95–$15.10 in EPS and declared a quarterly dividend of $0.88 per share.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $386.28 versus a recent share price near $330. However, insiders sold roughly $216.2 million of stock over the past 90 days, including a major sale by director Ronda E. Stryker.

Haverford Financial Services Inc. purchased a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,563 shares of the medical technology company's stock, valued at approximately $3,326,000.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. VanderPol Investments L.L.C. grew its holdings in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC raised its stake in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after purchasing an additional 28 shares in the last quarter. Rossby Financial LCC lifted its position in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC grew its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after buying an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC increased its holdings in Stryker by 0.6% in the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after buying an additional 30 shares during the period. Institutional investors own 77.09% of the company's stock.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the business's stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 665,370 shares of company stock valued at $216,238,501 in the last 90 days. Corporate insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $329.86 on Monday. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. The firm has a 50 day simple moving average of $326.99 and a 200 day simple moving average of $332.39.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SYK shares. BMO Capital Markets began coverage on shares of Stryker in a report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price target for the company. Wells Fargo & Company decreased their price objective on shares of Stryker from $456.00 to $418.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Piper Sandler lowered their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. Leerink Partners cut their target price on Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research note on Friday, June 5th. Finally, Truist Financial raised their target price on Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average price target of $386.28.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source